Skip to main content
SpringerLink
Log in

SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?

  • Coronary Heart Disease (S. Virani and M. Al Rifai, Section Editors)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

In this review, we discuss the mechanisms of action of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and the purported protective effects for mitigating heart failure (HF)-related outcomes.

Recent Findings

Major randomized clinical trials have demonstrated the cardiovascular safety and efficacy of SGLT-2i among patients without known HF and those with established HF with reduced ejection fraction or preserved ejection fraction (HFrEF and HFpEF respectively). Recent HF guidelines have incorporated SGLT-2i in HF treatment algorithms.

Summary

SGLT-2i have emerged as a novel treatment for both prevention of HF and reduction of cardiovascular morbidity and mortality among patients with existing HFrEF or HFpEF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14:30–8.

    Article  CAS  Google Scholar 

  2. McMurray JJ V, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993–1004.

  3. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726.

    Article  CAS  Google Scholar 

  4. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of Amer. Circulation. 2017;136:e137–61.

    Article  Google Scholar 

  5. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

    Article  CAS  Google Scholar 

  6. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet (London, England). 2019;393:31–9.

    Article  CAS  Google Scholar 

  7. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England). 2020;396:819–29.

    Article  Google Scholar 

  8. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020;17:559–73.

    Article  CAS  Google Scholar 

  9. Tsampasian V, Elghazaly H, Chattopadhyay R, et al. Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur. J Prev Cardiol. 2021:zwab189.

  10. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59:1333–9.

    Article  Google Scholar 

  11. McMurray J. EMPA-REG - the ‘diuretic hypothesis’. J. Diabetes Complications. 2016;30:3–4.

    Article  Google Scholar 

  12. van Brummelen P, Man in’t Veld AJ, Schalekamp MA. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther. 1980;27:328–36.

    Article  Google Scholar 

  13. van Brummelen P, Schalekamp MA. Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension. Acta Med Scand. 1980;207:259–64.

    Article  Google Scholar 

  14. Joubert M, Jagu B, Montaigne D, et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes. 2017;66:1030–40.

    Article  CAS  Google Scholar 

  15. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016;39:1115–22.

    Article  CAS  Google Scholar 

  16. Garcia-Ropero A, Santos-Gallego CG, Zafar MU, Badimon JJ. Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opin Drug Metab Toxicol. 2019;15:275–85.

    Article  CAS  Google Scholar 

  17. Maejima Y. SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function. Front. Cardiovasc. Med. 2020:6. https://www.frontiersin.org/article/10.3389/fcvm.2019.00186

  18. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108–17.

    Article  CAS  Google Scholar 

  19. Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens. 2020;29:190–8.

    Article  CAS  Google Scholar 

  20. Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2:1025–9.

    Article  Google Scholar 

  21. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.

    Article  CAS  Google Scholar 

  22. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57.

    Article  CAS  Google Scholar 

  23. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2020;384:129–39.

    Article  Google Scholar 

  24. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413–24. This is the second randomzied clinical trial showing the benefit of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) among patients with heart failure and reduced ejection fraction (HFrEF). This demonrated a class effect for SGLT-2i for reducing cardiovacular mortality and heart failure hospitlalization among patients with HFrEF.

  25. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995–2008. This is the first randomzied clinical trial showing the benefit of sodium-glucose cotransporter 2 inhibitors (SGLT-2i) for reducing cardiovacular mortality and heart failure hospitlalization among patients with known heart failure and reduced ejection fraction.

  26. Bhatt DL. Effect of sotagliflozin on cardiovascular events in patients with type 2 diabetes post worsening heart failure - SOLOIST-WHF. Eur. Soc. Cardiol. Virtual Congr. 2021. https://www.acc.org/latest-in-cardiology/clinical-trials/2020/11/11/22/00/soloist-whf.

  27. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451–61. This is the first randomzied clinical trial showing the benefit of a medication for reducing heart failure hospitalization among patients with heart failure and preserved ejection fraction.

  28. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial. Circulation. 2022;145:184–93.

    Article  CAS  Google Scholar 

  29. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 2019; published online March. https://doi.org/10.1161/CIRCULATIONAHA.119.040130.

  30. Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27:1954–60.

    Article  Google Scholar 

  31. Solomon SD, de Boer RA, DeMets D, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail. 2021;23:1217–25.

    Article  CAS  Google Scholar 

  32. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810–52.

    Article  Google Scholar 

  33. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J Card Fail. 2017;23:628–51.

    Article  Google Scholar 

  34. MT M, JJ L, AL A, et al. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol. 2021;77:772–810.

    Google Scholar 

  35. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895–1032.

  36. Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet (London, England). 2020;396:121–8.

    Article  CAS  Google Scholar 

  37. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition o. J Card Fail. 2021;27:387–413.

    Article  Google Scholar 

  38. Jia X, Mehta PB, Ye Y, Alam M, Birnbaum Y, Bajaj M. SGLT2 inhibitors and cardiovascular outcomes: current perspectives and future potentials. Curr Diab Rep. 2018;18:63.

    Article  Google Scholar 

  39. Eberly LA, Yang L, Eneanya ND, et al. Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Netw open. 2021;4:e216139–9.

    Article  Google Scholar 

  40. Rifai M Al, Mahtta D, Ramsey DJ, et al. Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: insights from the Department of Veterans Affairs. Am. Heart J. 2021; published online Dec. https://doi.org/10.1016/j.ahj.2021.12.006.

Download references

Author information

Authors and Affiliations

  1. Section of Cardiology, Department of Medicine, Baylor College of Medicine, 2002 Holcombe Blvd, Houston, TX, 77030, USA

    Mahmoud Al Rifai, Ajith P. Nair, Arunima Misra, Savitri Fedson & Salim S. Virani

  2. Department of Medicine, Division of Cardiology, Duke University School of Medicine, Raleigh, NC, USA

    L. Kristin Newby

  3. Duke Clinical Research Institute, Duke University School of Medicine, Raleigh, NC, USA

    L. Kristin Newby

  4. Division of Cardiology, Texas Heart Institute, Houston, TX, USA

    Joseph G. Rogers

  5. Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA

    Salim S. Virani

Authors
  1. Mahmoud Al Rifai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Kristin Newby
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ajith P. Nair
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arunima Misra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joseph G. Rogers
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Savitri Fedson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Salim S. Virani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Salim S. Virani.

Ethics declarations

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflict of Interest

Dr. Virani: Research support: Department of Veterans Affairs, National Institutes of Health, World Heart Federation, Tahir, and Jooma Family. Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org).

Dr. Virani serves as Section Editor for Current Atherosclerosis Reports.

Dr. Al Rifai serves as Section Editor for Current Atherosclerosis Reports.

Dr. Misra: Clinical trial subinvestigator, participated as local site subinvestigator for SOLOIST study, outside the submitted work.

Dr. Newby reports grants from BioKier, Roche Diagnostics, and Boehringer-Ingelheim; and personal fees from Beckman-Coulter and Medtronic, outside the submitted work.

The other authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Coronary Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Al Rifai, M., Newby, L.K., Nair, A.P. et al. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently?. Curr Atheroscler Rep 24, 627–634 (2022). https://doi.org/10.1007/s11883-022-01038-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-022-01038-2

Keywords

Search

Navigation